适当使用住院患者的红色素形成刺激剂
Chenghao Cui1, Timothy Nguyen2, Mohammad A Rattu1
1The Mount Sinai Hospital, New York, NY.
Innovations in pharmacy
|May 22, 2025
概括
红色素形成刺激剂 (ESAs) 用于治疗贫血,但具有风险. 西奈山医院的一项审查发现,住院ESA的使用非常合适,98.8%的剂量达到Hb目标,表明遵守最佳实践.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 贫血是一种全球性健康问题,与疲劳和虚弱有关.
- 红色素形成刺激剂 (ESAs) 增加血红蛋白 (Hb),但在12 g/dL以上带来心血管风险.
- 电子电子电子设备的安全性和适当使用是关键的公共卫生问题.
更多相关视频
08:53Author Spotlight: Advancing Erythropoiesis Research - A Simplified Pipeline for Assessing Hematopoietic Stem Cell Function in Myelodysplastic Syndromes
Published on: January 10, 2025
393
14:22Lentiviral-mediated Knockdown During Ex Vivo Erythropoiesis of Human Hematopoietic Stem Cells
Published on: July 16, 2011
13.1K
相关概念视频
Erythropoiesis
4.0K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.0K
Role of Hematopoietic Growth Factors
1.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.2K
Heart Failure Drugs: Inotropic Agents
481
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
481
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
141
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
141
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
121
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
121
